Literature DB >> 17824983

Prospective study of the diagnostic evaluation of faecal incontinence and leakage in male patients.

M Titi1, J T Jenkins, A Urie, R G Molloy.   

Abstract

OBJECTIVE: Male faecal incontinence (FI) has received little attention. No consistent pathophysiological abnormality has been identified in those studies that have specifically assessed male patients with FI or faecal leakage (FL). This study was designed to re-examine the different theories relating to the pathophysiology of male incontinence and to assess if manometric and ultrasound assessment yields clinically relevant information that directs patient care.
METHOD: This was a prospective study of all men referred to a Coloproctology clinic with incontinence. The Wexner Incontinence score was used to assess severity of symptoms. Specific investigations included anal manometry, rectal sensation and endo-anal ultrasound (EAUS). Results were compared with a group of 20 normal male controls.
RESULTS: A total of 59 symptomatic male patients were investigated (36 FI, 23 FL). FL and control groups had similar maximum resting (MRP) and maximum squeeze pressure (MSP). The incontinence group had a significantly lower MRP &amp; MSP compared with controls [MRP: FI 58 (42-75.5) vs control 85 (72-104)] (P < 0.0001), [MSP: FI 167 (125-215) vs control 248 (192-302)] (P < 0.0001). There was no significant difference in rectal sensation between the groups and the defecation index was also similar. EAUS detected only one external anal sphincter defect amongst the 23 male patients with FL. One external sphincter defect and three internal sphincter defects were identified amongst the 36 patients with incontinence. Of these five patients with sphincter defects, four had previously undergone anorectal surgery. [Results expressed as median (interquartile range): manometry expressed as mmHg].
CONCLUSION: Male patients presenting with faecal incontinence frequently show impaired sphincter function which may be associated with sphincter defects. In contrast, those presenting predominantly with FL have no morphological or physiological changes that might account for their symptoms. Investigating such patients with anorectal physiology and EAUS is usually unhelpful and can be omitted.

Entities:  

Mesh:

Year:  2007        PMID: 17824983     DOI: 10.1111/j.1463-1318.2006.01196.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  5 in total

1.  Rectal mucosal prolapse in males: surgery is effective for fecal incontinence but not for obstructed defecation.

Authors:  O Schwandner; B Schrinner
Journal:  Tech Coloproctol       Date:  2014-05-01       Impact factor: 3.781

2.  The relationship between etiology, symptom severity and indications of surgery in cases of anal incontinence: a 25-year analysis of 1,046 patients at a tertiary coloproctology practice.

Authors:  A Bondurri; A P Zbar; H Tapia; F Boffi; M Pescatori
Journal:  Tech Coloproctol       Date:  2011-05-03       Impact factor: 3.781

3.  Male faecal incontinence presents as two separate entities with implications for management.

Authors:  Muhammad Saeed Qureshi; Milind M Rao; Kishore K Sasapu; John Casey; Mehr-Un-Nisa Qureshi; Umar Sadat; David Hick; Simon Ambrose; David G Jayne
Journal:  Int J Colorectal Dis       Date:  2011-07-26       Impact factor: 2.571

4.  Fecal incontinence in men: causes and clinical and manometric features.

Authors:  Teresa Muñoz-Yagüe; Pablo Solís-Muñoz; Constanza Ciriza de los Ríos; Francisco Muñoz-Garrido; Jesús Vara; José Antonio Solís-Herruzo
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

5.  Long-term effects of neoadjuvant chemoradiotherapy followed by sphincter-preserving resection on anal sphincter function in relation to quality of life among locally advanced rectal cancer patients: a cross-sectional analysis.

Authors:  Zerrin Ozgen; Sevgi Ozden; Beste M Atasoy; Hazan Ozyurt; Rasim Gencosmanoglu; Nese Imeryuz
Journal:  Radiat Oncol       Date:  2015-08-12       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.